HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SBA Advocacy Office Joins Industry In Opposing AER Labeling Guidance

This article was originally published in The Tan Sheet

Executive Summary

FDA should "better analyze the possible effects" its adverse event reporting draft guidance will have on the dietary supplement industry, according to the Small Business Administration's independent Office of Advocacy

You may also be interested in...

FDA Estimates Dollar Costs For Adverse Event Labeling But Doubts Persist

FDA's estimate of nearly $44 million for the dietary supplement industry to revise labels to comply with the adverse event reporting law may understate the actual burden by leaving out some key costs

AER Label Guidance Holds To Requiring Full Addresses For OTCs, Supplements

FDA is extending the deadline for serious adverse event labeling requirements for OTC drugs and dietary supplements until January 2010 because it has yet to finalize its guidance to comply with those regulations

FDA’s AER Language Guidance Leaves Room For Interpretation – Consultants

As dietary supplement firms revise their product labels to reflect FDA's adverse event reporting draft guidance, some industry experts say acceptable changes are not as onerous as many have feared

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts